Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Nkarta Inc
NKTX | US
2.80
USD0.38
15.70%
NKTX | US
Loading StockChartView...
About Nkarta Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
2.80
Open
2.47
High
2.81
Low
2.46
Nkarta Inc. a clinical-stage biopharmaceutical company develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101 which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019 that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta Inc. was incorporated in 2015 and is based in South San Francisco California.
View LessNKTX | US
Risk
81.6
Sharpe
0.88
Luna's Score
54/100
Recommendation
Hold
Luna says (NKTX | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
100.4%1 month
81.6%3 months
77.0%6 months
66.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.62
Debt to equity
0.19
Debt to assets
0.15
Ent. to EBITDA
0.95
Ent. to rev.
1.00M
PEG
-
Other Fundamentals
EBITDA
-114.01M
MarketCap
197.56M
MarketCap(USD)
197.56M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-27.99
Short ratio
19.21
Short perc.
17.73
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.68
Range1M
0.85
Range3M
0.90
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
2.70
Price X volume
4.72M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.95 | 0.53 | Expensive |
| Ent. to Revenue | 1,000,000.00 | 3,967.00 | Expensive |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.62 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 77.03 | 72.80 | Par |
| Debt to Equity | 0.19 | -1.23 | Expensive |
| Debt to Assets | 0.15 | 0.25 | Cheaper |
| Market Cap | 197.56M | 3.66B | Emerging |
